Non‐Thermal Plasma as a Unique Delivery System of Short‐Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells-Reference-Cited by-同舟云学术

Non‐Thermal Plasma as a Unique Delivery System of Short‐Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells

Published:2019-01-28 Issue:6 Volume:6 Page:1802062
ISSN:2198-3844
Container-title:Advanced Science
language:en
Short-container-title:Adv. Sci.

Author:

Lin Abraham¹²^ORCID,Gorbanev Yury¹,De Backer Joey³,Van Loenhout Jinthe²,Van Boxem Wilma¹,Lemière Filip⁴,Cos Paul⁵,Dewilde Sylvia³,Smits Evelien²,Bogaerts Annemie¹

Affiliation:

1. Plasma, Laser Ablation, and Surface Modeling—Antwerp (PLASMANT)University of Antwerp Universiteitsplein 1 2610 Antwerpen‐Wilrijk Belgium

2. Center for Oncological Research (CORE)University of Antwerp Universiteitsplein 1 2610 Antwerpen‐Wilrijk Belgium

3. Department of Biomedical SciencesUniversity of Antwerp Universiteitsplein 1 2610 Antwerpen‐Wilrijk Belgium

4. Biomolecular and Analytical Mass Spectrometry (BAMS) GroupDepartment of Chemistry & Centre for ProteomicsUniversity of Antwerp Groenenborgerlaan 171 2020 Antwerpen Belgium

5. Department of Pharmaceutical SciencesUniversity of Antwerp Universiteitsplein 1 2610 Antwerpen‐Wilrijk Belgium

Funder

Flanders Research Foundation

European Marie Sklodowska-Curie Individual Fellowship within Horizon2020

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.201802062

Reference48 articles.

1. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3. Oncology Meets Immunology: The Cancer-Immunity Cycle

4. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

5. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium;Redox Biology;2024-02

2. Eco‐friendly materials for next‐generation vaccination: From concept to clinical reality;SmartMat;2024-01-31

3. In silico study of the impact of oxidation on pyruvate transmission across the hVDAC1 protein channel;Archives of Biochemistry and Biophysics;2024-01

4. Cold atmospheric plasma activated media selectively affects human head and neck cancer cell lines;2023-12-14

5. Gas plasmas technology: from biomolecule redox research to medical therapy;Biochemical Society Transactions;2023-12-13